Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Federal Trade Commission
Merck
Colorcon
Cipla
AstraZeneca
McKesson
Mallinckrodt

Generated: April 24, 2018

DrugPatentWatch Database Preview

MAVIK Drug Profile

« Back to Dashboard

When do Mavik patents expire, and what generic alternatives are available?

Mavik is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in MAVIK is trandolapril. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the trandolapril profile page.
Drug patent expirations by year for MAVIK
Synonyms for MAVIK
(2S,3aR,7aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydro-1H-indole-2-carboxylic acid
(2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
(2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid
(2s,3ar,7as)-1-[(2s)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxidanylidene-4-phenyl-butan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid
(2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
1H-Indole-2-carboxylic acid, 1-((2S)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-
1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))-
1T0N3G9CRC
679T376
87679-37-6
A842336
AC1NUNSR
AK163083
AKOS015843316
AKOS015896050
AM035968
API0004465
AX8035229
BDBM50369775
BG0519
BIDD:GT0804
C24H34N2O5
CAS-87679-37-6
CCG-222228
CCRIS 6594
CHEBI:9649
CHEMBL1519
CI-907
CS-2809
CTK8E8021
D00383
D0M5OC
DB00519
DR002663
DSSTox_CID_3692
DSSTox_GSID_23692
DSSTox_RID_77151
DTXSID2023692
FT-0082544
Gopten
GTPL6453
HMS3262J10
HY-B0592
I06-1849
Indolapril
KB-81195
KS-1467
LP00924
LS-82763
Mavik (TN)
MFCD00865776
MolPort-006-167-568
NCGC00095153-01
NCGC00182079-02
NCGC00182079-03
NCGC00261609-01
Odric
Odrik
Preran
RU 44570
RU-44570
RU44570
SC-17973
SCHEMBL16610
SR-02000000917
SR-02000000917-2
ST24050183
TC-070968
Tox21_111453
Tox21_113152
Tox21_500924
trandolapril
Trandolapril (JAN/INN)
Trandolapril [INN:BAN]
Trandolapril [USP:INN:BAN]
Trandolapril, >=98% (HPLC), white powder
Trandolapril, European Pharmacopoeia (EP) Reference Standard
Trandolapril, United States Pharmacopeia (USP) Reference Standard
Trandolaprilum
Trandolaprilum [Latin]
Udrik
UNII-1T0N3G9CRC
VXFJYXUZANRPDJ-WTNASJBWSA-N
ZINC1853205

US Patents and Regulatory Information for MAVIK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for MAVIK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 ➤ Sign Up ➤ Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 ➤ Sign Up ➤ Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 ➤ Sign Up ➤ Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MAVIK
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Federal Trade Commission
Medtronic
Citi
Teva
UBS
Chubb
Deloitte
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.